EntryPoint Capital LLC Boosts Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

EntryPoint Capital LLC increased its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 127.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,495 shares of the company’s stock after acquiring an additional 34,468 shares during the quarter. EntryPoint Capital LLC’s holdings in Taysha Gene Therapies were worth $106,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares during the period. Vanguard Group Inc. boosted its holdings in Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after buying an additional 641,305 shares during the period. Wellington Management Group LLP purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth $931,000. Barclays PLC raised its holdings in Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after acquiring an additional 193,046 shares during the period. Finally, State Street Corp lifted its position in shares of Taysha Gene Therapies by 4.5% in the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $1.93 on Monday. The company has a market cap of $395.65 million, a price-to-earnings ratio of 3.06 and a beta of 0.91. Taysha Gene Therapies, Inc. has a 1 year low of $1.19 and a 1 year high of $4.32. The stock’s 50 day simple moving average is $1.65 and its two-hundred day simple moving average is $1.91. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. As a group, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TSHA shares. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.